No abstract available.
Quetiapine Fumarate ; Stroke

OBJECTIVE: The aim of this study was to demonstrate changes of clinical benefit and subjective wellbeing after once-daily extended release quetiapine furmate (quetiapine XR) in patients with schizophrenia. METHODS: In a naturalistic, observational, and multicentric study, 1,494 patients with schizophrenia who switched to quetiapine XR (flexible dosing) due to insufficient efficacy or intolerance were recruited. Clinical Global Impressions-Clinical Benefit (CGI-CB), CGI-Severity (CGI-S), CGI-Improvement (CGI-I) and Subjective Wellbeing under Neuroleptic Treatment Scale (SWN-K) were assessed at baseline and after 8 weeks treatment. We also examined factors related to changes of CGI-CB and SWN-K scores using linear regression analysis. RESULTS: Among 1,494 patients, 1,342 patients (89.8%) completed this study and 1,204 patients (80.6%) without protocol violation were included in the analysis. The mean dose of quetiapine XR was 416.9+/-205.8 mg/day at the initiation and continuously increased to 591.6+/-228.3 mg/day until week 5. At the endpoint, the mean dose of quetiapine XR was 580.24+/-382.24 mg/day. Both CGI-CB and CGI-S scores were significantly decreased after 8 weeks (both p<0.0001) and 745 patients (61.9%) achieved clinical benefit. Mean CGI-I scores were 2.49+/-0.80 and the response rate defined as CGI-I< or =2 was 51.6%. Subjective wellbeing scores were increased after 8 weeks (p<0.0001). Improvements of CGI-CB and subjective wellbeing were associated with quetiapine XR dosages as well as age and baseline scores. CONCLUSION: After switching to quetiapine XR, 61.9% of patients with schizophrenia who had a history of unsatisfactory treatment (efficacy or tolerance) showed clinical benefit and subjective wellbeing was significantly increased. Regarding that dosages of quetiapine XR were associated with improvements of clinical benefit and subjective wellbeing, active treatment strategies with higher dosages of quetiapine XR could be suggested in the real field.
Dibenzothiazepines ; Humans ; Linear Models ; Schizophrenia ; Quetiapine Fumarate

Charles Bonnet syndrome (CBS) can develop after trans-sphenoidal adenomectomy (TSA); however, the neural mechanisms remain unknown. Sensory deprivation and releasing phenomenon are both hypothetical explanations for this condition; however, there is no definite evidence that strongly supports either supposition. We report the first case of CBS after TSA without optic nerve atrophy. Postoperatively, the patient's vision seemed to be relatively well preserved, apart from the left-side hemianopsia in the right eye. Distinctive visual hallucinations only appeared when his eyes were closed, and these responded to quetiapine in a dose-dependent manner. Dose dependent change in colors and formation of hallucination was reported. Two weeks after quetiapine initiation, the patient's CBS was completely resolved. This unique case suggests that blocking sensory input from the periphery is more critical than neural damage of the bottom-up connection to the visual association cortex. In addition, quetiapine should be considered as a specific treatment for CBS.
Atrophy* ; Hallucinations ; Hemianopsia ; Optic Nerve* ; Quetiapine Fumarate ; Sensory Deprivation

OBJECTIVES: Many studies showed that risperidone and olanzapine in the treatment of delirium were similar to haloperidol, in side effects were superior to that. Quetiapine is frequently used in delirious patients. However, the studies of quetiapine in the treatment of delirium are very few. This study was designed to compare the efficacy of risperidone and quetiapine in elderly patients with delirium. METHODS: We divided 2 groups (risperidone and quetiapine) of elderly patients with delirium. We compared the two groups of elderly patients with delirium by Korean Version of Delirium Rating Scale (K-DRS) and Korean Mini-Mental State Examination (K-MMSE) at baseline and 1 week later. RESULTS: Our results showed that risperidone and quetiapine were efficacious in the treatment of elderly patients with delirium according to using K-DRS and K-MMSE. There were no significant differences in the degree of effects in both drugs. CONCLUSION: We compared the efficacy of risperidone and quetiapine in the treatment of delirium. Quetiapine was as efficacious as risperidone in the treatment of the elderly patients with delirium. In future, the sample size need to be increased in the studies of delirium. And the evaluation of long-term side effects related to quetiapine need to be performed.
Aged* ; Delirium* ; Haloperidol ; Humans ; Risperidone* ; Sample Size ; Quetiapine Fumarate

OBJECTIVES: This study was conducted to evaluate the overall effectiveness and tolerability of adjunctive quetiapine in the long-term treatment of bipolar disorder as a continuation therapy. METHODS: Twenty-three bipolar I patients participated and required to have quetiapine add-on treatment in combination with existing or new mood stabilizers. Clinical assessment was carried out using Young Mania Rating Scale (YMRS), Clinical Global Impression (CGI), Hamilton Depression Rating Scale-17 item, Simpson-Angus Rating Scale and Barnes Akathisia Rating Scale at baseline, 1, 4, 12 and 24 weeks. RESULTS: The YMRS and CGI decreased significantly from baseline to endpoint by 89.7% and 78.3%, respectively (p<0.0001 ; p<0.0001). Twenty-two patients exhibited at least 50% improvement on YMRS score by the end of the study. CONCLUSION: This study suggests that quetiapine may hold a promise as an adjunct in the long-term treatment of bipolar disorder.
Bipolar Disorder* ; Depression ; Humans ; Prospective Studies* ; Psychomotor Agitation ; Quetiapine Fumarate

The case of a 77-year-old man with Charles Bonnet syndrome was presented. This patient lost his vision due to glaucoma, and he subsequently developed complex visual hallucinations. No other psychotic symptoms (e.g., delusions, perceptual disturbances) and no evidence of cognitive impairment or neurological diseases were reported. The visual hallucinations disappeared after treatment with quetiapine, an atypical antipsychotic, without any side effects. The visual hallucinations reappeared after quetiapine was discontinued. Treatment with a small dose of quetiapine has been maintained to prevent the exacerbation of symptoms.
Aged ; Delusions ; Dibenzothiazepines ; Glaucoma ; Hallucinations ; Humans ; Vision, Ocular ; Quetiapine Fumarate

OBJECTIVE: The purpose of the study is to compare treatment responses and side effects of antipsychotic medications in hospitalized delirium patients. METHODS: Among delirium patients hospitalized 23 less-sedating agent group and 26 sedating agent group were included in the study. Less sedating agents are haloperidol and risperidone, and sedating agents are olanzapine and quetiapine. All candidates underwent Clinical Global Impression Scale (CGI), Delirium Rating Scale-Revised 98 (DRS-R 98), and Extrapyramidal Symptom Rating Scale during the treatment period. At baseline, 1st day, 2nd day, 3rd day, 4th day, 5th day, 6th day, 7th day, 10th day, and 14th day, we compared treatment responses and side effect profiles between two groups. RESULTS: The remission defined as below 16 score of DRS-R 98, and the remission rate of both group were 78.3% at less-sedating agent group, and 80.8% at sedating agent group. They showed no difference each other. Time to remission of less-sedating group was significantly shorter than sedating group, they were 2.89+/-1.41 days at less-sedating agent group, and 5.76+/-4.45 days at sedating agent group (p=0.015). After 2 days of treatment, less-sedating agent group showed greater decrement of CGI-S score than sedating agent group, the score were 3.22+/-1.20 at less-sedating agent, and 4.00+/-1.22 at sedating agent group (p=0.030). And DRS-R 98 score after 2 days of treatment showed difference between both group, less-sedating agent group was 17.00+/-8.88, and sedating group was 22.72+/-8.49, they were different statistically (p=0.044). The mean dosage of each drugs were haloperidol 1.93 mg, risperidone 0.71 mg, olanzapine 3.75 mg, and quetiapine 46.09 mg. But there were no significant differences of rate of adverse effects. CONCLUSION: There were no differences of total remission rate and rate of adverse effects between two groups for 2 weeks. But less-sedating agent group showed shorter time to remission and shorter duration of medication than sedating agent group. This study suggests that less-sedating agents are more suitable for early days of delirium treatment.
Antipsychotic Agents* ; Delirium* ; Haloperidol ; Humans ; Hypnotics and Sedatives* ; Risperidone ; Quetiapine Fumarate

OBJECTIVES: The purpose of this study is to examine the efficacy and side effects of quetiapine and haloperidol for the treatment of symptoms of delirium. METHODS: One hundred and seven patients with delirium were recruited and randomly assigned to receive a flexible-dose regimen of quetiapine or haloperidol over 7days and seventy-seven patients completed the study(quetiapine group N=40, haloperidol group N=37). The severity of delirium was assessed by using Memorial Delirium Assessment Scale(MDAS) scores, the psychiatric and behavioral symptoms were assessed by Neurobehavioral Rating Scale(NRS) scores, and the cognitive status was measured by Mini-mental state examination Korean version(MMSE-K) scores. The side effects were measured by Drug Induced Extrapyramidal Symptoms Scale(DIEPSS) scores. RESULTS: MDAS scores significantly improved in both treatment groups. NRS scores also significantly improved in both treatment group, but the group-by-time effect approached significance, likely caused by the greater decrease in scores of the quetiapine group. MMSE-K scores significantly improved only in the quetiapine group. Side effects associated with treatment were not significant in either treatment groups. CONCLUSION: This study suggests that quetiapine is as efficacious as haloperidol in the treatment of delirium. In particular, quetiapine seems to improve psychiatric and behavioral problems of delirium and was more effective than haloperidol in cognitive improvement.
Behavioral Symptoms ; Delirium ; Dibenzothiazepines ; Haloperidol ; Humans ; Prospective Studies ; Quetiapine Fumarate

A woman in her twenties with schizophrenia developed immediate-onset mania after taking oral aripiprazole and receiving aripiprazole long-acting injection (ALAI). The dosage of aripiprazole was rapidly increased due to inadequate stimulating effect of low-dosage aripiprazole, but her manic symptomatology worsened. Clinicians should therefore carefully monitor for the induction of mania by oral aripiprazole and ALAI. Her manic symptomatology improved after adding 20 mg of blonanserin, 3 mg of risperidone, and 300 mg of quetiapine.
Aripiprazole ; Bipolar Disorder ; Female ; Humans ; Quetiapine Fumarate ; Risperidone ; Schizophrenia

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is associated with severe skin eruptions, fever, hematological abnormalities, and multi-organ involvement. Although aromatic anticonvulsant drugs have been frequently associated with the manifestation of DRESS syndrome, its induction following treatment with nonaromatic anticonvulsants, such as valproate, has rarely been reported. Moreover, there are limited data regarding the development of neosensitization related to chemically unrelated drugs following an episode of DRESS syndrome. Here, a case of neosensitization to multiple drugs is described. The present case report describes a female patient who experienced neosensitization to amoxicillin, olanzapine, and quetiapine following the manifestation of DRESS syndrome induced by valproate.
Amoxicillin ; Anticonvulsants ; Drug Hypersensitivity Syndrome* ; Female ; Fever ; Humans ; Quetiapine Fumarate ; Skin ; Valproic Acid